REG - Byotrol PLC - US EPA approves Byotrol24 as long-lasting virucide

ByotrolAnnouncement

24/05/2023 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230524:nRSX5499Aa&default-theme=true

RNS Number : 5499A  Byotrol PLC  24 May 2023

 

 

 

 

Byotrol Plc

 

("Byotrol" or the "Company")

 

EPA approval for

long-lasting performance against viruses

 

Byotrol Plc (AIM: BYOT), the specialist infection prevention and control
company, is pleased to announce that the US Environmental Protection
Agency ("EPA") has formally approved long-lasting virucidal claims for its
proprietary 24-hour germ-kill surface sanitizer Byotrol 24 (EPA Reg. Number
83614-1).  This approval was received by the Company after close of business,
on 22 May 2023.

 

The Directors believe that this is the first product to receive such EPA
approval and means that Byotrol24 and its sub brands will now be able to offer
unique and highly relevant claims and performance characteristics to US
consumers and businesses.   This includes being able to claim efficacy
against certain current and emerging viral pathogens including influenza,
coronavirus and norovirus (via the commonly accepted surrogate feline
calicivirus).

The Company continues to advance alliances and commercial opportunities in the
US, including with a previously announced, well-known sub-licensee in the US
institutional market, which is continuing to prepare a market launch with the
new product claims at the forefront of its marketing strategy.

 David Traynor, Executive Director,  Byotrol plc comments:

 "This is fantastic news for Byotrol and confirms the excellence of our US
surface sanitizers.

Customers and consumers are now as concerned about protecting against viruses
as well as bacteria.  This new approval means we can now make specific
long-lasting efficacy claims against viruses, which should in turn
significantly increase the commercial potential of our US formulations."

 

 

For further information contact:

 

 Byotrol Plc
 David Traynor, Executive Director                                                    +44 (0)1925 742 000

 Dr Trevor Francis, Non- Executive Chairman
 Vivan Pinto, Chief Executive Officer

 Chris Sedwell, Chief Financial Officer

 finnCap Limited (Nominated Adviser and Broker)                                       +44 (0)20 7220 0500
 Geoff Nash/George Dollemore - Corporate Finance

 Nigel Birks/Harriet Ward - ECM

 Flagstaff Strategic and Investor Communications                                      +44 (0)20 7129 1474
 Tim Thompson/Andrea Seymour/Fergus Mellon                                            byotrol@flagstaffcomms.com (mailto:byotrol@flagstaffcomms.com)

 

 

 

 

This announcement is released by Byotrol Plc and, prior to publication, the
information contained herein was deemed to constitute inside information under
the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed
in accordance with the Company's obligations under Article 17 of MAR.

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and
control company, operating globally in the Healthcare, Industrial, Food and
Consumer sectors, providing low toxicity products with a broad-based and
targeted efficacy across all microbial classes; bacteria, viruses (including
coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing
products, where they can significantly improve their performance, especially
in personal hygiene, domestic and industrial disinfection, odour control, food
production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and
cleaner lives for everyone.

 

For more information, go to byotrol.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUSASROUUVUAR